Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
18 mai 2022 17h00 HE
|
Adamis Pharmaceuticals Corporation
David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE)...
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
16 mai 2022 16h35 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
09 mai 2022 17h56 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
31 mars 2022 16h49 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
24 mars 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
22 mars 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas...
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
18 févr. 2022 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
23 nov. 2021 14h39 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
19 nov. 2021 15h34 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
04 oct. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s...